2023-503620-60-00招募中1 期
A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 49
- 试验地点
- 9
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
CTIS Point of Contact
Scientific
Janssen - Cilag International
研究点 (9)
Loading locations...
相似试验
招募中
不适用
A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple MyelomaKahler's disease10018865Multiple MyelomaNL-OMON53994Janssen-Cilag14
进行中（未招募）
1 期
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple MyelomaMultiple MyelomaNCT05050097Janssen Research & Development, LLC166
招募中
3 期
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Daratumumab (SC) and Pomalidomide (Tal-DP) or Talquetamab (SC) in combination with Daratumumab SC (Tal-D) versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy10018865Multiple MyelomaNL-OMON53729Janssen-Cilag25
招募中
3 期
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants with Relapsed or Refractory Myeloma who Have Received an Anti-CD38 Antibody and LenalidomideCTRI/2024/02/063266Johnson and Johnson Private Limited
招募中
1 期
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and LenalidomideRelapsed or Refractory MyelomaMedDRA version: 21.1Level: PTClassification code: 10035226Term: Plasma cell myeloma Class: 100000004864CTIS2022-502446-27-00Janssen - Cilag International827